Matthew Winton serves as Executive at Inozyme Pharma, Inc., where they oversee executive responsibilities. Since joining the company, Matthew Winton has executed 5 insider transactions totaling $117.1K, demonstrating a bullish approach to their equity position. Their most recent transaction on Nov 18, 2025 involved purchasing 1,500 shares valued at $11.9K.
Matthew Winton currently holds 15,000 shares of Inozyme Pharma, Inc. (INZY), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Winton has been a net buyer of INZY stock. They have purchased $117.1K and sold $0 worth of shares.
Matthew Winton's most recent insider trade was on Nov 18, 2025, when they purchased 1,500 shares at $7.95 per share.
Get notified when new Form 4 filings are submitted
| $8.43 |
| Discretionary |
| Nov 14, 2025 | CRVO | $75.7K | Purchase | 10,000 | $7.57 | Discretionary |
| Jul 1, 2025 | INZY | $87.0K | Tender | 21,743 | $4.00 | Discretionary |
| Mar 28, 2024 | INZY | $10.6K | Award | 3,188 | $3.33 | Discretionary |